Bystolic

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bystolic

Property Description
Active Ingredient Nebivolol hydrochloride
Form Tablet (Oral)
Pharmacological Class Beta-Adrenergic Blocking Agent (Beta-Blocker)
Common Use Cardiovascular support
Origin Synthetic

Bystolic is a prescription medication formulated as a tablet for oral administration, containing the sole active ingredient Nebivolol hydrochloride. This compound is chemically synthesized, classifying it as a synthetic pharmaceutical product. Nebivolol belongs to the drug class known as beta-adrenergic blocking agents, or beta-blockers. Its differentiating feature is its advanced profile relative to older beta-blockers, offering targeted action and unique vascular benefits.


Pharmacological Classification of Nebivolol

Nebivolol is identified as a third-generation, highly selective beta1-antagonist, a specific classification that sets it apart within the beta-blocker class. This means its action is focused primarily on the beta-1 receptors in the heart (cardioselective properties), offering concentrated effects on cardiac function. A distinguishing factor for Nebivolol is its direct promotion of vasodilation, or the widening of blood vessels, which is uncommon among selective beta1 agents. This property is achieved by stimulating the release of nitric oxide from the blood vessel lining. This dual mechanism—combining heart rate moderation with arterial widening—is a specific characteristic of Nebivolol.


General Purpose of the Medication

The core purpose of Nebivolol's dual action is to effectively reduce the overall functional demand on the heart and to support blood vessel health. By moderating the heartbeat and supporting the relaxation of arteries, the medication is generally used in scenarios requiring sustained cardiovascular support. The medication supports the maintenance of healthy blood flow and pressure dynamics.

What side effects are possible with Bystolic?

The official safety profile for nebivolol is structured by categorizing documented adverse reactions based on their frequency and the physiological system affected, providing a non-interpretive framework for its safety characteristics.

Frequency-Classified Adverse Reactions

The most frequently reported effects in regulatory data are classified as Common, occurring in up to 1 in 10 people. These typically include headache, dizziness, and fatigue, along with gastrointestinal effects such as constipation or diarrhoea. Reactions classified as Uncommon include bradycardia (slowed heart rate), hypotension (low blood pressure), depression, and impotence.

Classification Examples of Affected Systems and Reactions
Common Nervous system (Headache, Dizziness), Gastrointestinal (Nausea, Diarrhoea), General (Fatigue, Oedema)
Uncommon Cardiac disorders (Bradycardia), Vascular disorders (Hypotension), Psychiatric disorders (Depression)

Serious Adverse Reactions and Safety Constraints

Official labeling documents serious risks, including the potential for severe exacerbation of angina or myocardial infarction when the treatment is abruptly discontinued in patients with existing coronary artery disease. The medication is contraindicated in individuals with severe, pre-existing conditions such as cardiogenic shock, decompensated heart failure, severe bradycardia, and severe hepatic impairment. The drug's beta-blocking activity may mask the symptoms of other conditions, notably hypoglycemia in diabetic patients and the rapid heart rate associated with hyperthyroidism.

Safety notes for specific populations state that use is contraindicated in severe hepatic impairment, and that a dosage reduction is necessary for those with severe renal impairment. The regulatory framework establishes that documented risks during pregnancy include the potential for fetal/neonatal harm.

Overdose and Emergency Response

The official regulatory profile for Bystolic (Nebivolol) overdose is defined by documented physiological disturbances resulting from excessive drug effect. The most common clinical manifestations listed in prescribing information are bradycardia (abnormally slow heart rate) and hypotension (abnormally low blood pressure). Other documented presentations include cardiac failure, dizziness, hypoglycemia (low blood sugar), fatigue, and vomiting. Further documented risks include manifestations typically associated with beta-blockade, such as bronchospasm and heart block.


Emergency Actions and Documented Outcomes

The official documents state that an overdose may lead to serious or life-threatening outcomes, including second or third-degree heart block and respiratory failure. Urgent medical attention is required immediately to provide general supportive and specific symptomatic treatment for these severe manifestations.

The official procedures described in regulatory labeling include targeted interventions for specific symptoms, such as the use of IV atropine, vasopressors, IV fluids, and potential pacemaker placement for severe cardiovascular instability. Management is strictly supportive, as the labeling confirms that hemodialysis is not expected to enhance clearance and no specific antidote is known. These regulatory statements define the conditions under which emergency medical help must be sought.

Therapeutic Uses of Bystolic

The primary therapeutic domain for Bystolic (nebivolol) is the long-term management of essential hypertension, or chronically high blood pressure, in adults. It is commonly used across conditions marked by a persistent elevation of blood pressure readings. This medication is generally considered relevant in conditions characterized by chronic, established heart disease, including essential hypertension, is considered relevant for easing symptoms linked to organ-specific functional stress in conditions involving increased physiological stress for certain patient groups, and plays a role in managing symptoms that interfere with daily comfort, such as angina. This treatment generally contributes to improved day-to-day comfort and stability and assists in managing the factors associated with cardiovascular risk.

The medication is applied in clinical settings that involve heightened physiological tension. It is commonly used to help with symptomatic discomfort and strain, especially in settings marked by temporary physiological imbalance. The medication may assist with managing reduced blood vessel flexibility, which generally contributes to maintaining functional stability.


Quick Fact: Relief for Elevated Arterial Pressure Bystolic supports patients during episodes of heightened discomfort by helping with symptomatic discomfort and strain, and is relevant for managing symptoms that interfere with daily comfort.

Eligibility and Restrictions for Use

Official Eligibility and Restrictions

Bystolic (nebivolol) is officially restricted for use in populations based on specific, severe medical conditions and age. Eligibility is defined by the absence of formal contraindications listed in regulatory labeling.

Classification Populations Who Must NOT Use the Medicine
Absolute Contraindications Severe bradycardia, heart block greater than first degree, cardiogenic shock, or decompensated cardiac failure.
Other Contraindications Sick sinus syndrome (unless a permanent pacemaker is in place), severe hepatic impairment (Child-Pugh Class C), and known hypersensitivity to any component of the product.

Restricted and Not Recommended Use

The medicine is not approved for use in children under 18 years of age as safety and effectiveness have not been established in the pediatric population. Use is generally not recommended in patients with severe renal impairment (creatinine clearance <30 mL/min) or moderate hepatic impairment (Child-Pugh Class B), where reduced initial doses are recommended if used. Additionally, caution is advised for patients with bronchospastic diseases, and breastfeeding is not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for nebivolol’s interactions is defined by two primary categories: pharmacokinetic alteration, which modifies drug exposure, and pharmacodynamic effects, which create additive cardiovascular risks.


Exposure-Altering Interactions

Nebivolol is metabolized by the CYP2D6 enzyme. Co-administration with CYP2D6 enzyme inhibitors (such as Quinidine, Propafenone, Fluoxetine, or Paroxetine) is officially documented to increase the systemic exposure of nebivolol, an effect that may require a regulatory-guided dose modification.

To prevent a documented decrease in absorption, administration of nebivolol must be separated by at least 2 hours from antacids and multivitamin/mineral products.


Pharmacodynamic Interactions and Constraints

Concomitant use with agents that share cardiovascular effects requires monitoring. Non-Dihydropyridine Calcium Channel Blockers (e.g., Verapamil, Diltiazem) may lead to excessive reductions in heart rate and cardiac contractility. Combining nebivolol with Digitalis Glycosides is documented to increase the risk of bradycardia due to additive effects on heart conduction. Co-administration with other beta-blockers is generally prohibited due to the risk of additive effects. Furthermore, using nebivolol with Alcohol (Ethanol) may result in officially documented additive effects in lowering blood pressure.

In specific populations, the interaction context is altered: in patients with severe hepatic impairment, the official label documents that nebivolol exposure is increased 10-fold.

Mechanism of Action

Selective Beta-1 Adrenergic Receptor Blockade

Bystolic (nebivolol) acts as a highly selective antagonist of beta-1 (beta1) adrenergic receptors located primarily on cardiac cells. This interaction prevents the binding of endogenous signaling molecules, norepinephrine and epinephrine, resulting in the modulation of the sympathetic nervous system.

Dual Mechanism: Cardiac Modulation and Vasodilation

This blockade produces two physiological changes: a decrease in heart rate (negative chronotropy) and a decrease in the force of heart contraction (negative inotropy), which reduce cardiac output. Separately, nebivolol stimulates the release of nitric oxide (NO) from the vascular endothelium. NO acts as a signaling molecule that causes vascular smooth muscle to relax, leading to vasodilation and a reduction in systemic vascular resistance (SVR). The integration of reduced cardiac output with reduced peripheral resistance results in the combined modulation of cardiac function and vascular tone, producing the physiological effect of reduced arterial pressure.

Dosage and Administration Information

How to Use Bystolic: Dosing and Administration

Bystolic (nebivolol) is prescribed for the long-term management of essential hypertension and is administered solely via the oral route as a tablet. The medication is intended for chronic use, requiring a structured approach to achieve a stable maintenance dose over time.

Standard Dosing Regimen

Feature General Instruction
Administration Route Oral (by mouth)
Frequency Pattern Once daily
Starting Dose (Adults) 5 mg once daily for hypertension.
Maximum Dose (Adults) 40 mg once daily.
Titration Schedule Dose adjustments should occur at 2-week intervals.

Contextual Usage Instructions

Nebivolol tablets may be taken with or without food. Administration should occur at the same time each day to maintain consistent medication levels. If a dose is missed, it should be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose; patients must not double the dose to compensate.

For patients with certain health conditions, adjustments to the standard regimen are required. The recommended starting dose is reduced to 2.5 mg once daily for individuals with severe renal impairment (creatinine clearance less than 30 mL/min) or moderate hepatic impairment. Use is not recommended for patients with severe hepatic impairment.

Treatment is part of a long-term therapeutic plan. Should therapy need to be discontinued, the standard protocol involves the dose being gradually reduced over a period of approximately 1 to 2 weeks to ensure a safe transition off the medication.

Recent Clinical Evidence

Research evidence / Overview of studies for Bystolic

Evidence Supporting the Use in Chronic High Blood Pressure

Nebivolol was studied for its intended use in randomized, double-blind, placebo-controlled trials (RCTs), which contribute substantially to the research landscape. Research also included trials examining nebivolol against other types of beta-blockers. The main focus of these studies was to measure changes in Sitting Diastolic Blood Pressure (SiDBP) and Sitting Systolic Blood Pressure (SiSBP), which are key outcomes monitoring physiological strain or stress. The study populations were primarily adults diagnosed with mild to moderate high blood pressure.

Research highlights changes measured during the study period, with data showing patterns related to measured blood pressure measurements over short intervals. However, the core evidence is often derived from trials with relatively limited follow-up durations, typically lasting only a few weeks. This means that long-term effects are not fully established by these initial trials.


Evidence Supporting the Use in Chronic Heart Failure in Older Adults

Nebivolol was studied for its use in heart failure in large-scale Phase III trials, including the key SENIORS study. This research explored outcomes related to systemic or functional imbalance in a specific patient group. The primary goal of these trials was to explore major clinical events, such as the composite outcome of all-cause mortality and hospitalization due to cardiovascular issues. These studies tracked changes in the heart's pumping ability (e.g., LVEF) and how daily functioning or activity level was observed in patients.

The primary limitation here is that the main evidence is concentrated on older adults (age ge 70 years), which means the results apply only to the populations studied and do not necessarily extend to younger patients with heart failure. Furthermore, comparative evidence is lacking against other established heart failure treatments in some areas.


What Remains Uncertain or Under Research

Research provides context but not individual predictions, and evidence highlights what is known and what is still uncertain about the medication. Long-term effects are not fully established for the maintenance of blood pressure patterns or stable symptom patterns over many years. The results apply only to the populations studied, meaning data are still emerging or limited for patients with highly complex comorbidities or specific subgroups.

Key Studies & References Nebivolol - StatPearls (General authoritative overview and pharmacological context)

Frequently Asked Questions (FAQ)

Common questions about Bystolic (FAQ)


Q: What are the most common side effects people report when taking Bystolic?

A: Regulatory documents state that the most commonly reported side effects include fatigue (tiredness), headache, dizziness, and gastrointestinal effects such as diarrhea or nausea. These effects are generally classified as common, meaning they occur more frequently in clinical data.


Q: Does Bystolic cause weight gain?

A: Weight gain itself is not explicitly listed in the frequency-classified side effects in the official documentation. However, related issues such as fluid retention or edema (swelling) are sometimes documented as an effect of the medication.


Q: Is feeling dizzy a normal side effect of Bystolic?

A: Official information confirms that dizziness is a common adverse reaction associated with Bystolic. This means that dizziness is among the effects most frequently reported in patient studies and regulatory data.


Q: What happens if a dose of Bystolic is missed?

A: Regulatory instructions state that if a dose is forgotten, it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the forgotten dose is typically skipped. Official regulatory instructions state that a patient should not take two doses to make up for the missed one.


Q: Are there any known foods or drinks that interact with Bystolic?

A: Official regulatory information specifically addresses certain products, stating that the administration of Bystolic must be separated by at least two hours from antacids and multivitamin/mineral products. This is done to prevent a documented decrease in the absorption of the medicine.


Q: Is it safe to drink alcohol while using Bystolic?

A: The official product profile documents that consuming alcohol (ethanol) may have additive effects in lowering blood pressure when combined with Bystolic. Any decision regarding alcohol use should be discussed in the context of one's overall health plan.


Q: Does Bystolic interact with common pain relievers like ibuprofen?

A: Pain relievers known as Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which include ibuprofen, may reduce the blood pressure-lowering effect of beta-blockers. Official information notes that monitoring may be considered when NSAIDs are used in patients being treated for high blood pressure or heart conditions.


Q: Can people with asthma or COPD use Bystolic?

A: Official guidelines indicate that special consideration is required when the medicine is prescribed to patients with bronchospastic diseases, a category that includes conditions like asthma or Chronic Obstructive Pulmonary Disease (COPD).


Q: Can Bystolic cause fatigue or tiredness?

A: Fatigue is officially documented as a common adverse reaction. This is one of the more frequently reported effects in clinical trial data.


Q: Is it common to have trouble sleeping while taking Bystolic?

A: Trouble sleeping, or insomnia, is officially documented in regulatory data as an uncommon adverse reaction. This means it is reported less frequently than the common side effects.


Q: Can taking Bystolic affect athletic performance?

A: Bystolic is known to work by decreasing the heart rate and the force of heart contraction. This action reduces the heart’s overall workload and functional demand, which is the mechanism that may affect a person's physical tolerance for certain strenuous activities.


Q: Are there any reports of mood changes or depression linked to Bystolic?

A: Official regulatory documentation lists depression as an uncommon adverse reaction. Patients should be aware that mood changes are reported, though infrequently, in connection with the medication.


Q: How does Bystolic compare generally to other blood pressure medicines?

A: The official description notes that Bystolic is classified as a third-generation beta-blocker. It works by blocking receptors in the heart while also promoting the widening of blood vessels through the release of nitric oxide. This dual mechanism is a distinguishing characteristic within the class of beta-blockers.


Q: Is Bystolic used for anxiety or just for blood pressure?

A: Bystolic is officially approved and indicated only for the treatment of essential hypertension (high blood pressure). Approved indications are limited to this use.


Q: What should be done before switching from another beta-blocker to Bystolic?

A: The official discontinuation protocol for beta-blockers generally states that the dose must be gradually reduced over a period of one to two weeks. This structured process should be followed when transitioning between different beta-blocker therapies.


Q: Does Bystolic have different effects on men versus women?

A: The regulatory label documents known safety constraints and specific considerations for women related to pregnancy and lactation. However, official information does not provide details on different treatment effects based on biological sex.


Q: Do doctors ever prescribe Bystolic for migraine prevention?

A: Bystolic is officially approved and indicated only for the treatment of hypertension (high blood pressure). Approved uses are limited to this indication.


Q: Can Bystolic be taken with acid reflux medications?

A: Official drug interaction checkers typically show no reported interaction with common acid reflux medications, such as omeprazole. Checking for potential interactions remains a key element of the medication plan.


Q: What are the withdrawal symptoms described for stopping Bystolic?

A: Official regulatory information documents that abruptly stopping treatment may cause severe health consequences, particularly for patients with existing coronary artery disease. These risks include the exacerbation of angina (chest pain) or myocardial infarction (heart attack).


Q: Does Bystolic interact with cold and flu medicines?

A: Many over-the-counter cold and flu medicines contain sympathomimetic agents that can potentially counteract the blood pressure-lowering effect of Bystolic. Combining them may result in additive effects on heart rate and blood pressure.


Q: Is Bystolic a medication that has to be taken lifelong?

A: Bystolic is approved for the long-term management of essential hypertension. Since hypertension is typically a chronic condition, the medicine is generally intended for continuous, ongoing treatment.


Q: What happens to the heart when taking Bystolic?

A: According to the official mechanism of action, the medicine reduces the heart’s workload. It achieves this by decreasing the heart rate and reducing the force of the heart’s contraction.


Q: Why is Bystolic not for everyone who has high blood pressure?

A: The medicine is contraindicated, or officially prohibited, for individuals with certain severe pre-existing medical conditions. These conditions include cardiogenic shock, certain heart blocks, or severe hepatic impairment (severe liver issues).


Q: Is it normal to have cold hands and feet when using Bystolic?

A: While not explicitly listed as a common reaction in all official materials, cold extremities (hands and feet) are an effect commonly associated with the beta-blocker class of medicines, to which Bystolic belongs.


Q: How do medical professionals decide who is eligible for Bystolic?

A: Eligibility is fundamentally based on the absence of medical conditions that are officially listed as contraindications in the regulatory labeling. These contraindications include severe heart rhythm problems and certain organ impairments.


Q: Has Bystolic been studied in pediatric populations?

A: Official information states that Bystolic is not approved for use in children under 18 years of age. This is because safety and effectiveness for use in the pediatric population have not been established.


Q: Is it common to need a dosage change after starting Bystolic?

A: Official instructions specify that dose adjustments should occur at structured intervals, typically every two weeks, until a patient achieves a stable maintenance dose. This suggests that initial dosage changes are part of the standard treatment process.


Q: Can Bystolic cause sexual side effects?

A: Official documentation lists impotence as an uncommon adverse reaction associated with the medication.


Q: What is the maximum approved dosage for Bystolic?

A: Official regulatory documents state that the maximum labeled dose for adults with hypertension is 40 mg taken once daily.


Q: Are there any long-term health risks associated with taking Bystolic?

A: Official research evidence notes that long-term effects for continuous use over many years are not fully established by the initial clinical trials, which often had limited follow-up durations.


Q: Can Bystolic affect blood sugar levels?

A: The medicine's beta-blocking activity may mask some of the typical physical symptoms of hypoglycemia (low blood sugar), such as a rapid heart rate, in patients who have diabetes. This is an official safety precaution.

How should Bystolic be stored and disposed of?

How to Store and Dispose of Bystolic (nebivolol hydrochloride)

The official storage and disposal requirements for Bystolic tablets are strictly defined by regulatory standards to maintain product stability and safety.


Storage Requirements

Bystolic must be stored at controlled room temperature, specifically between 20^circmathrmC and 25^circmathrmC (68^circmathrmF and 77^circmathrmF). Brief temperature excursions are permitted, ranging from 15^circmathrmC to 30^circmathrmC (59^circmathrmF to 86^circmathrmF). The product must be kept in a location that is out of the reach of children.


Disposal Requirements

Unused or expired Bystolic should be disposed of through a drug take-back program or mail-back envelope as the preferred method. If take-back is unavailable, the tablets must be mixed with an undesirable substance (e.g., dirt or cat litter) in a sealed container and placed in the household trash; do not crush the tablets. Bystolic is not recommended for disposal by flushing and must be discarded in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bystolic found in:

A-Z Index: